Abstract
BackgroundLymph node metastasis of triple-negative breast cancer (TNBC) is essential in treatment strategy formulation. This study aimed to build a nomogram that predicts lymph node metastasis in patients with TNBC.Materials and MethodsA total of 28,966 TNBC patients diagnosed from 2010 to 2017 in the Surveillance, Epidemiology and End Results (SEER) database were enrolled, and randomized 1:1 into the training and validation sets, respectively. Univariate and multivariate logistic regression analysis were applied to identify the predictive factors, which composed the nomogram. The receiver operating characteristic curves showed the efficacy of the nomogram.ResultMultivariate logistic regression analyses revealed that age, race, tumor size, tumor primary site, and pathological grade were independent predictive factors of lymph node status. Integrating these independent predictive factors, a nomogram was successfully developed for predicting lymph node status, and further validated in the validation set. The areas under the receiver operating characteristic curves of the nomogram in the training and validation sets were 0.684 and 0.689 respectively, showing a satisfactory performance.ConclusionWe constructed a nomogram to predict the lymph node status in TNBC patients. After further validation in additional large cohorts, the nomogram developed here would do better in predicting, providing more information for staging and treatment, and enabling tailored treatment in TNBC patients.
Highlights
IntroductionTriplenegative breast cancer (TNBC) represents one of the subtypes described in recent years, which does not express estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2)
Breast cancer, the most common malignant tumor in women, is a heterogeneous disease
Analysis cohorts were identified according to the following criteria: unilateral, invasive carcinoma of the breast (ICD-O-3 8500); diagnosis confirmed by positive histology and not by autopsy or a death certificate, as the first and only primary tumor; adjusted AJCC stage I–III; known tumor size; histological grade I–III; known regional lymph node status; estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) negative
Summary
Triplenegative breast cancer (TNBC) represents one of the subtypes described in recent years, which does not express estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2). It shows a variety of biological, clinicopathological and molecular characteristics, responses significantly differently to treatment and achieves divergent prognosis [1, 2]. Patients with TNBC are more likely to show lymph node metastasis at the initial diagnosis [4]. Lymph node metastasis of triple-negative breast cancer (TNBC) is essential in treatment strategy formulation. This study aimed to build a nomogram that predicts lymph node metastasis in patients with TNBC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
